Upper gastrointestinal cancer and reflux disease

Journal of Gastric Cancer

Volumn 13, Issue 2, 2013, Pages 79-85

  Kim, Jin Jo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Fundoplication; Gastroesophageal reflux disease; Gastrointestinal cancer

Indexed keywords

PROTON PUMP INHIBITOR;

CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; KOREA; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH FUNDOPLICATION;

EID: 84879432501     PISSN: 2093582X     EISSN: 20935641     Source Type: Journal    
DOI: 10.5230/jgc.2013.13.2.79     Document Type: Review

References (76)

1. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma. N Engl J Med 1999;340:825-831.
2. Thrift AP, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarci-noma. Front Oncol 2012;2:11.
3. Lundell LR. Etiology and risk factors for esophageal carcinoma. Dig Dis 2010;28:641-644.
4. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-925.
5. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aeti-ologies of gastric cardia cancer. Gut 2008;57:298-305.
6. Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, et al. Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evi-dence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 2011;46:710-719.
7. Nunobe S, Nakanishi Y, Taniguchi H, Sasako M, Sano T, Kato H, et al. Two distinct pathways of tumorigenesis of adenocarci-nomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int 2007;57:315-321.
8. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009;18:469-485.
9. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G, et al. Barrett's esophagus and esophageal cancer: an overview. Int J Oncol 2012;41:414-424.
10. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg 2011;15:708-718.
11. Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, et al. Prevalence of gastroesophageal reflux disease in Korea and as-sociated health-care utilization: a national population-based study. J Gastroenterol Hepatol 2012;27:741-745.
12. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-735.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO-CAN 2008. Int J Cancer 2010;127:2893-2917.
14. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
15. Fujiwara Y, Takahashi S, Arakawa T, Sollano JD, Zhu Q, Kachintorn U, et al; IGICS Study Group. A 2008 questionnaire-based survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries. Digestion 2009;80:119-128.
16. Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-207.
17. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study. Am J Gastroenterol 2006;101:1193-1199.
18. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-477.
19. Rubenstein JH, Taylor JB. Meta-analysis: the association of oe-sophageal adenocarcinoma with symptoms of gastro-oesopha-geal reflux. Aliment Pharmacol Ther 2010;32:1222-1227.
20. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471-1478.
21. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esopha-geal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
22. Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O'Rourke RW, et al. Gastroesophageal reflux disease symp-tom severity, proton pump inhibitor use, and esophageal carci-nogenesis. Arch Surg 2011;146:851-858.
23. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesopha-geal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004;20:637-643.
24. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, et al; Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is in-dependent of environmental and genetic modifiers. Gastroen-terology 2010;139:73-83.
25. Blaser MJ. Disappearing microbiota: Helicobacter pylori pro-tection against esophageal adenocarcinoma. Cancer Prev Res (Phila) 2008;1:308-311.
26. Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocar-cinoma--a systematic review and meta-analysis. Ann Oncol 2011;22:754-760.
27. Islami F, Kamangar F. Helicobacter pylori and esophageal can-cer risk: a meta-analysis. Cancer Prev Res (Phila) 2008;1:329-338.
28. 2010 Annual report of the Korea central cancer registry. Avail-able at: http://www.ncc.re.kr/ Accessed May 30, 2013.
29. Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, et al. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 1994;73:2691-2694.
30. Hansson LR, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995;109:885-888.
31. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA nega-tive Helicobacter pylori infection. Gut 1997;40:297-301.
32. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yama-guchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
33. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125:666-673.
34. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-256.
35. Kim JY, Lee HS, Kim N, Shin CM, Lee SH, Park YS, et al. Prev-alence and clinicopathologic characteristics of gastric cardia cancer in South Korea. Helicobacter 2012;17:358-368.
36. Lee JY, Kim HY, Kim KH, Jang HJ, Kim JB, Lee JH, et al. No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci 2003;18:53-57.
37. Kim JI, Kim SG, Kim N, Kim JG, Shin SJ, Kim SW, et al; Korean College of Helicobacter and Upper Gastrointestinal Research. Changing prevalence of upper gastrointestinal dis-ease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787-793.
38. Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Ber-gethon K, Mandal R, et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011;24:1177-1190.
39. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gas-troenterology 1991;101:1149-1158.
40. Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid sup-pression. Aliment Pharmacol Ther 2001;15:269-276.
41. Orlando RC. Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am 2005;89:219-241.
42. Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, et al. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci 2011;1232:1-17.
43. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995;222:525-531.
44. Kauer WK, Stein HJ. Emerging concepts of bile reflux in the constellation of gastroesophageal reflux disease. J Gastrointest Surg 2010;14 Suppl 1:S9-16.
45. Bremner CG, Lynch VP, Ellis FH Jr. Barrett's esophagus: con-genital or acquired? An experimental study of esophageal mu-cosal regeneration in the dog. Surgery 1970;68:209-216.
46. Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP. Experi-mental columnar metaplasia in the canine oesophagus. Br J Surg 1988;75:113-115.
47. Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology 1983;85:621-628.
48. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the develop-ment of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-370.
49. Cheng P, Li JS, Gong J, Zhang LF, Chen RZ. Effects of refluxate pH values on duodenogastroesophageal reflux-induced esoph-ageal adenocarcinoma. World J Gastroenterol 2011;17:3060-3065.
50. Yamada T, Ishida Y, Nakamura Y, Shimada S. Bile-acid-induced calcium signaling in mouse esophageal epithelial cells. Biochem Biophys Res Commun 2011;414:789-794.
51. Zhang T, Zhang F, Han Y, Gu Z, Zhou Y, Cheng Q, et al. A rat surgical model of esophageal metaplasia and adenocarcinoma-induced by mixed reflux of gastric acid and duodenal contents. Dig Dis Sci 2007;52:3202-3208.
52. Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Rit-ter MP, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J Gastrointest Surg 1998;2:260-268.
53. Vaezi MF, Richter JE. Role of acid and duodenogastroesopha-geal reflux in gastroesophageal reflux disease. Gastroenterol-ogy 1996;111:1192-1199.
54. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Du-odenogastroesophageal reflux: relationship to pH and impor-tance in Barrett's esophagus. Gastroenterology 1994;107:747-754.
55. Waring JP, Legrand J, Chinichian A, Sanowski RA. Duodeno-gastric reflux in patients with Barrett's esophagus. Dig Dis Sci 1990;35:759-762.
56. Lirón R, Parrilla P, Martinez de Haro LF, Ortiz A, Robles R, Luján JA, et al. Quantification of duodenogastric reflux in Bar-rett's esophagus. Am J Gastroenterol 1997;92:32-36.
57. Stein HJ, Feussner H, Kauer W, DeMeester TR, Siewert JR. Alkaline gastroesophageal reflux: assessment by ambula-tory esophageal aspiration and pH monitoring. Am J Surg 1994;167:163-168.
58. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997;122:874-881.
59. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP.Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 1995;82:657-660.
60. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complica-tions of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline expo-sure, and duodenogastric reflux. Ann Surg 1992;216:35-43.
61. Hopwood D, Bateson MC, Milne G, Bouchier IA. Effects of bile acids and hydrogen ion on the fine structure of oesopha-geal epithelium. Gut 1981;22:306-311.
62. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602.
63. Bajpai M, Aviv H, Das KM. Prolonged exposure to acid and bile induces chromosome abnormalities that precede malig-nant transformation of benign Barrett's epithelium. Mol Cyto-genet 2012;5:43.
64. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-2338.
65. Ye W, Chow WH, Lagergren J, Yin L, Nyrén O. Risk of adeno-carcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121:1286-1293.
66. DeMeester SR. Antireflux surgery and the risk of esophageal adenocarcinoma: an antithetical view of the data from sweden. Ann Surg 2013;257:583-585.
67. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003;238:458-464.
68. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, De-Meester SR, Crookes PF, et al. Long-term outcome of antire-flux surgery in patients with Barrett's esophagus. Ann Surg 2001;234:532-538.
69. Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, et al. Antireflux surgery normalizes cyclooxygen-ase-2 expression in squamous epithelium of the distal esopha-gus. Am J Gastroenterol 2006;101:1458-1466.
70. Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux sur-gery. Arch Surg 2007;142:554-559.
71. Martinez de Haro LF, Ortiz A, Parrilla P, Munitiz V, Martinez CM, Revilla B, et al. Long-term follow-up of malignancy bio-markers in patients with Barrett's esophagus undergoing medi-cal or surgical treatment. Ann Surg 2012;255:916-921.
72. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-1606.
73. Tamhankar AP, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, et al. Omeprazole does not reduce gastroesopha-geal reflux: new insights using multichannel intraluminal im-pedance technology. J Gastrointest Surg 2004;8:890-897.
74. Gutschow CA, Bludau M, Vallböhmer D, Schröder W, Bollsch-weiler E, Hölscher AH. NERD, GERD, and Barrett's esopha-gus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring. Dig Dis Sci 2008;53:3076-3081.
75. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 1998;2:333-341.
76. Lee SK, Kim EK. Laparoscopic Nissen fundoplication in Ko-rean patients with gastroesophageal reflux disease. Yonsei Med J 2009;50:89-94.